MedTrace Logo

Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms

NCT07664696 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-06-24

No results posted yet for this study

Summary

Investigational New Drug trial investigating safety as primary endpoint and clinical efficacy as secondary endpoint of placental, mesenchymal stem cell-derived extracellular vesicles for the treatment of COVID-19 symptoms in adults with mild to moderate illness.

Conditions

Interventions

BIOLOGICAL

IV infusion using an isolated, placental, mesenchymal stem cell derived EVs

Single IV infusion of the drug product XoGlo Pro

BIOLOGICAL

Placebo IV administration

Placebo IV infusion of normal saline

Sponsors & Collaborators

  • Kimera Labs Inc.

    lead INDUSTRY

Principal Investigators

  • Dr. Azza Halim, MD · Kimera Labs Inc. - CMO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-01-31
Primary Completion
2028-06-30
Completion
2028-12-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07664696 on ClinicalTrials.gov